Compare Stocks: VSTM, CDNA, PHVS, and VERA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$46.51 +0.7%	$34.87	$11.27 ▼ $49.76	$2.39B	2.39	1.12 million shs	1.89 million shs
PHVS Pharvaris	$36.27 +0.5%	$33.97	$20.65 ▼ $36.93	$2.36B	-2.31	518,874 shs	1.04 million shs
VERA Vera Therapeutics	$32.28	$36.40	$21.15 ▼ $56.05	$2.33B	0.92	2.15 million shs	1.26 million shs
VSTM Verastem	$7.30 -1.7%	$5.37	$3.43 ▼ $11.24	$672.89M	0.26	2.01 million shs	2.35 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+0.71%	-1.69%	+21.21%	+115.62%	+301.99%
PHVS Pharvaris	+0.47%	-0.52%	+8.11%	+18.76%	+55.93%
VERA Vera Therapeutics	0.00%	+7.64%	-12.73%	-6.03%	+46.26%
VSTM Verastem	-1.75%	+5.04%	+26.96%	+70.96%	-6.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDNA CareDx	$46.51 +0.7%	$34.87	$11.27 ▼ $49.76	$2.39B	2.39	1.12 million shs	1.89 million shs
PHVS Pharvaris	$36.27 +0.5%	$33.97	$20.65 ▼ $36.93	$2.36B	-2.31	518,874 shs	1.04 million shs
VERA Vera Therapeutics	$32.28	$36.40	$21.15 ▼ $56.05	$2.33B	0.92	2.15 million shs	1.26 million shs
VSTM Verastem	$7.30 -1.7%	$5.37	$3.43 ▼ $11.24	$672.89M	0.26	2.01 million shs	2.35 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDNA CareDx	+0.71%	-1.69%	+21.21%	+115.62%	+301.99%
PHVS Pharvaris	+0.47%	-0.52%	+8.11%	+18.76%	+55.93%
VERA Vera Therapeutics	0.00%	+7.64%	-12.73%	-6.03%	+46.26%
VSTM Verastem	-1.75%	+5.04%	+26.96%	+70.96%	-6.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDNA CareDx	2.57	Moderate Buy	$47.75	2.67% Upside
PHVS Pharvaris	2.86	Moderate Buy	$51.08	40.82% Upside
VERA Vera Therapeutics	2.86	Moderate Buy	$81.15	151.41% Upside
VSTM Verastem	2.91	Moderate Buy	$13.83	89.50% Upside

Current Analyst Ratings Breakdown

Latest VSTM, CDNA, PHVS, and VERA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	VERA Vera Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$34.00
8/14/2026	PHVS Pharvaris	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$60.00
8/14/2026	PHVS Pharvaris	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
8/13/2026	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/13/2026	PHVS Pharvaris	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Overweight
8/13/2026	PHVS Pharvaris	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/13/2026	PHVS Pharvaris	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$51.00 ➝ $52.00
8/13/2026	PHVS Pharvaris	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$74.00 ➝ $75.00
8/12/2026	VERA Vera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$125.00 ➝ $90.00
8/11/2026	VERA Vera Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$84.00

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDNA CareDx	$379.80M	6.33	$0.01 per share	7,090.00	$8.23 per share	5.65
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.35 per share	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$5.66 per share	N/A
VSTM Verastem	$30.91M	21.39	N/A	N/A	$0.55 per share	13.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDNA CareDx	-$21.35M	$2.07	22.47	73.83	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
PHVS Pharvaris	-$198.79M	-$3.05	N/A	N/A	N/A	N/A	-61.40%	-56.00%	N/A
VERA Vera Therapeutics	-$299.61M	-$5.86	N/A	N/A	N/A	N/A	-84.13%	-66.79%	11/4/2026 (Estimated)
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-467.49%	-94.54%	11/3/2026 (Estimated)

Latest VSTM, CDNA, PHVS, and VERA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	PHVS Pharvaris	-$0.7467	-$0.81	-$0.0633	-$0.80	N/A	N/A
8/10/2026	Q2 2026	VERA Vera Therapeutics	-$1.58	-$1.52	+$0.06	-$1.52	$1.28 million	N/A
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDNA CareDx	N/A	4.58	4.51
PHVS Pharvaris	N/A	11.94	11.94
VERA Vera Therapeutics	0.18	10.92	10.92
VSTM Verastem	1.48	2.25	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDNA CareDx	N/A
PHVS Pharvaris	N/A
VERA Vera Therapeutics	99.21%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
CDNA CareDx	2.40%
PHVS Pharvaris	11.84%
VERA Vera Therapeutics	15.90%
VSTM Verastem	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDNA CareDx	740	51.73 million	50.49 million	Optionable
PHVS Pharvaris	30	65.41 million	57.66 million	Not Optionable
VERA Vera Therapeutics	40	72.06 million	60.61 million	Optionable
VSTM Verastem	50	90.56 million	88.81 million	Optionable

VSTM, CDNA, PHVS, and VERA Headlines

Recent News About These Companies

Verastem (NASDAQ:VSTM) Shares Up 6.4% - What's Next?

August 17 at 2:39 PM | marketbeat.com

Verastem (NASDAQ:VSTM) Downgraded to "Sell" Rating by Wall Street Zen

August 15, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen

August 15, 2026 | marketbeat.com

Verastem (VSTM) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM

August 12, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Shares Gap Up on Earnings Beat

August 9, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS

August 7, 2026 | marketbeat.com

Verastem Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verastem (NASDAQ:VSTM) Shares Gap Up Following Better-Than-Expected Earnings

August 7, 2026 | marketbeat.com

Verastem Restructures Oberland Financing to Support Commercialization

August 7, 2026 | tipranks.com

Verastem, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Verastem Reiterated as Buy on Strong AVMAPKI FAKZYNJA Momentum, VS-7375 Progress; $18 Price Target Maintained

August 7, 2026 | tipranks.com

Verastem: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

August 6, 2026 | finance.yahoo.com

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Moderate Buy" by Brokerages

August 2, 2026 | marketbeat.com

Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer

July 30, 2026 | tipranks.com

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic ...

July 30, 2026 | finance.yahoo.com

Verastem Oncology (NASDAQ:VSTM) Draws Fresh Market Focus

July 30, 2026 | kalkinemedia.comK

Verastem (VSTM) to Post Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, CDNA, PHVS, and VERA Company Descriptions

CareDx NASDAQ:CDNA

$46.51 +0.33 (+0.71%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$46.90 +0.39 (+0.83%)

As of 04:01 AM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Pharvaris NASDAQ:PHVS

$36.27 +0.17 (+0.47%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$36.30 +0.03 (+0.08%)

As of 08/19/2026 07:32 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Vera Therapeutics NASDAQ:VERA

$32.28 0.00 (0.00%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$32.76 +0.48 (+1.50%)

As of 04:01 AM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Verastem NASDAQ:VSTM

$7.30 -0.13 (-1.75%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$7.57 +0.27 (+3.68%)

As of 04:00 AM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VSTM, CDNA, PHVS, and VERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VSTM, CDNA, PHVS, and VERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VSTM, CDNA, PHVS, and VERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, CDNA, PHVS, and VERA Company Descriptions

CareDx NASDAQ:CDNA

Pharvaris NASDAQ:PHVS

Vera Therapeutics NASDAQ:VERA

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VSTM, CDNA, PHVS, and VERA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VSTM, CDNA, PHVS, and VERA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VSTM, CDNA, PHVS, and VERA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VSTM, CDNA, PHVS, and VERA Company Descriptions

CareDx NASDAQ:CDNA

Pharvaris NASDAQ:PHVS

Vera Therapeutics NASDAQ:VERA

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools